NCT00834808View on ClinicalTrials.gov

A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Healthy
Interventions
DRUG

Tramadol HCl

One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.

Sponsors

Lead Sponsor

Labopharm Inc.
All Listed Sponsors
lead

Labopharm Inc.

INDUSTRY

NCT00834808 - A Dose Linearity Study of the Labopharm Formulation of Tramadol HCl/Contramid®, 100 mg, 200 mg and 300 mg After A Single Oral Administration In Fasting Condition, In Healthy Human Volunteers | Biotech Hunter | Biotech Hunter